Canaccord Genuity Downgrades ResMed to Hold From Buy
Canaccord Genuity lowered its rating on ResMed to Hold from Buy.
Related stories
Oracle Shares Fall After Announcing Stock and Bond Transactions
Oracle announced stock transactions and bond transactions; its shares fell.
L impact | EQUITY | Nov 02, 2026, 01:56 PM UTC
Fox Reports Higher Q1 FY27 EPS and Revenue
Fox reported year-over-year increases in Q1 FY27 earnings per share and revenue.
M impact | EQUITY | Nov 02, 2026, 01:47 PM UTC
IDEXX Executive Says Covet Revenue Run Rate Is About $20 Million
An IDEXX executive said Covet revenue is growing at strong double-digit rates.
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Infineon and Qualcomm Technologies Sign Automated Driving Agreement
M impact | EQUITY | Nov 02, 2026, 01:46 PM UTC
Fox Shares Rise After Q1 Results Top Estimates
Fox shares rise after first-quarter results top estimates, supported by advertising.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC
AAR Proposes $955 Million and $960 Million Senior Note Offerings
AAR proposed $955 million of senior notes due 2031 and $960 million of senior notes due 2034.
M impact | EQUITY | Nov 02, 2026, 01:45 PM UTC